Scholarlink

<p>We investigated statin-based peptidomimetic compounds as inhibitors of SARS-CoV-2 papain-like protease (PLpro) by in silico methods, including molecular docking/dynamic simulations and ADMET prediction, as well as enzymatic in vitro assays. Five compounds (LQMed <b>426</b>, <b>428</b>,<b> 430</b>, <b>431</b>, and <b>432</b>) were identified as having promising interactions with the active site and an allosteric site of PLpro. The docking poses in the active site revealed that the compounds interacted with the catalytic triad (Cys111, His272, and Asp286). Compound <b>426</b> stood out for forming significant hydrophobic interactions and hydrogen bonds. In molecular dynamic (MD) simulations, there was a tendency for the compounds to migrate to a pocket in the ubiquitin-like (Ubl) domain region, indicating possible allosteric inhibition. Principal component analysis (PCA) and free energy landscape (FEL) plot showed significant differences in the conformational stability of protein-ligand complexes. Complex <b>432</b> had the highest stability (PC1: 24.9%, PC2: 10.5%) with restricted movements, while complex <b>430</b> had the lowest stability and the highest PC1, indicating broader movements. Complexes <b>426</b> and <b>428</b> had intermediate stability. FEL analysis confirmed that complex <b>432</b> had multiple minimum energy clusters, suggesting a greater likelihood of stable enzyme-ligand complex. In vitro assays demonstrated that all compounds inhibited PLpro activity by at least 50%, with IC<sub>50</sub> values ranging from 0.85 µM to 4.06 µM. Compounds <b>426</b> and <b>432</b> were the most promising, with IC<sub>50</sub> of 0.85 µM and 1.46 µM, respectively, values comparable to the <b>GRL-0617</b> reference inhibitor. Binding free energy analysis indicated that compounds <b>430</b> and <b>431</b> showed significant affinity for the allosteric site (-27&#xa0;kcal/mol and − 14&#xa0;kcal/mol, respectively), while compound <b>428</b> showed reduced stability. In addition, in silico pharmacokinetics and toxicity (ADMET) prediction revealed that statine-based compounds are promising compared to <b>GRL-0617</b> due to the low potential of inhibition of CYP’s family and toxicity risk. Overall, the tested compounds, especially <b>426</b> and <b>432</b>, showed potential as inhibitors of SARS-CoV-2 PLpro and may act by non-competitive or mixed mechanisms, making them promising candidates for developing antivirals against CoViD-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Statine-based peptidomimetics as SARS-CoV-2 Papain-like protease inhibitors: in Silico and in vitro studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月20日

查看全文
  • Raiane Dandara Pereira Pimentel,
  • Priscila Goes Camargo,
  • Pedro Henrique R. de A. Azevedo,
  • Larissa Esteves Carvalho Constant,
  • Stephany da Silva Costa,
  • Diego Allonso,
  • Carlos Rangel Rodrigues,
  • Magaly Girão Albuquerque,
  • Luiza R. S. Dias,
  • Estela Maris F. Muri,
  • Camilo Henrique da Silva Lima

摘要

We investigated statin-based peptidomimetic compounds as inhibitors of SARS-CoV-2 papain-like protease (PLpro) by in silico methods, including molecular docking/dynamic simulations and ADMET prediction, as well as enzymatic in vitro assays. Five compounds (LQMed 426, 428, 430, 431, and 432) were identified as having promising interactions with the active site and an allosteric site of PLpro. The docking poses in the active site revealed that the compounds interacted with the catalytic triad (Cys111, His272, and Asp286). Compound 426 stood out for forming significant hydrophobic interactions and hydrogen bonds. In molecular dynamic (MD) simulations, there was a tendency for the compounds to migrate to a pocket in the ubiquitin-like (Ubl) domain region, indicating possible allosteric inhibition. Principal component analysis (PCA) and free energy landscape (FEL) plot showed significant differences in the conformational stability of protein-ligand complexes. Complex 432 had the highest stability (PC1: 24.9%, PC2: 10.5%) with restricted movements, while complex 430 had the lowest stability and the highest PC1, indicating broader movements. Complexes 426 and 428 had intermediate stability. FEL analysis confirmed that complex 432 had multiple minimum energy clusters, suggesting a greater likelihood of stable enzyme-ligand complex. In vitro assays demonstrated that all compounds inhibited PLpro activity by at least 50%, with IC50 values ranging from 0.85 µM to 4.06 µM. Compounds 426 and 432 were the most promising, with IC50 of 0.85 µM and 1.46 µM, respectively, values comparable to the GRL-0617 reference inhibitor. Binding free energy analysis indicated that compounds 430 and 431 showed significant affinity for the allosteric site (-27 kcal/mol and − 14 kcal/mol, respectively), while compound 428 showed reduced stability. In addition, in silico pharmacokinetics and toxicity (ADMET) prediction revealed that statine-based compounds are promising compared to GRL-0617 due to the low potential of inhibition of CYP’s family and toxicity risk. Overall, the tested compounds, especially 426 and 432, showed potential as inhibitors of SARS-CoV-2 PLpro and may act by non-competitive or mixed mechanisms, making them promising candidates for developing antivirals against CoViD-19.